Accuray Incorporated (ARAY) vs Harvard Bioscience, Inc. (HBIO)

A side-by-side comparison of Accuray Incorporated and Harvard Bioscience, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ARAY vs HBIO

growth of $100 · dividends reinvested · last 10y
ARAY -94.9% (-25.7%/yr)HBIO -67.3% (-10.6%/yr)HBIO compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $10020182020202220242026$5$33
ARAY HBIO

ARAY vs HBIO: by the numbers

  • •HBIO is the larger company ($39M vs $37M market cap).
  • •Both run net losses; HBIO's is the smaller (-11.86% vs -12.24% net margin).
  • •ARAY grew revenue faster over the past five years (0.28% vs -4.62% CAGR).

Metrics side by side

Valuation

MetricARAYHBIO
P/S ratio0.090.44
P/B ratio0.895.24
EV / EBITDAN/A10.58

Profitability

MetricARAYHBIO
Gross margin27.73%58.16%
Operating margin-6.58%1.17%
Net margin-12.24%-11.86%
ROE-117.97%-140.36%
ROIC-10.09%1.99%

Growth (annualized)

MetricARAYHBIO
Revenue CAGR (5Y)0.28%-4.62%
Total return CAGR (5Y)-39.94%-34.33%

Frequently asked

Which has grown faster, ARAY or HBIO?
Over the past five years, ARAY grew revenue faster — ARAY at a 0.28% CAGR versus HBIO at -4.62%.
How have ARAY and HBIO total returns compared?
Over the past 10 years, ARAY delivered -25.77% and HBIO delivered -11.05% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.